eClinical Technology and Industry News

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

Excerpt from the Press Release:

SAN DIEGO, July 2, 2025 /PRNewswire/ — A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinicians monitor treatment response.

Study Highlights

  • Innovative Approach: The SeekInClarity test integrates genomic, epigenetic, and proteomic signals from blood samples to calculate a molecular tumor burden (MTB) score, offering a non-invasive alternative to traditional imaging-based assessments.
  • Clinical Validation: In a cohort of 116 newly diagnosed lymphoma patients, higher MTB scores strongly correlated with advanced tumor stage. Patients whose MTB status remained positive after two treatment cycles had significantly worse progression-free and overall survival.
  • Superior Risk Stratification: The study found that molecular response, as measured by SeekInClarity, and interim PET/CT were the only independent predictors of treatment outcome—outperforming established clinical biomarkers such as B2M and LDH.
  • Added Value Beyond Imaging: Among patients with interim PET/CT response, SeekInClarity identified a subgroup of molecular non-responders who were at substantially higher risk of disease progression, particularly in aggressive lymphoma subtypes.

Clinical Impact

Current standards for monitoring lymphoma rely on PET-CT or CT imaging, which can be costly and have limitations in sensitivity. The SeekInClarity assay provides a cost-effective, pan-indication blood test that can refine risk stratification and enable earlier intervention for patients unlikely to respond to standard therapies.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Categories

Archives